Does the media favor STEX or MDAI?

In the previous week, Spectral AI had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 6 mentions for Spectral AI and 5 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.79 beat Spectral AI's score of 0.23 indicating that Biosig Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RXST or MDAI more profitable?

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Spectral AI -85.58% N/A -72.97%

Does the media favor RXST or MDAI?

In the previous week, Spectral AI had 4 more articles in the media than RxSight. MarketBeat recorded 6 mentions for Spectral AI and 2 mentions for RxSight. RxSight's average media sentiment score of 0.93 beat Spectral AI's score of 0.23 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MDAI or PROF?

In the previous week, Spectral AI had 4 more articles in the media than Profound Medical. MarketBeat recorded 6 mentions for Spectral AI and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat Spectral AI's score of 0.23 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Spectral AI (MDAI) Competitors

$2.03 -0.04 (-1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.74%)

As of 07:57 PM Eastern

Compare

MDAI vs. SGHT, STEX, RXST, PROF, and OBIO

Should you buy Spectral AI stock or one of its competitors? MarketBeat compares Spectral AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral AI include Sight Sciences (SGHT), Biosig Technologies (STEX), RxSight (RXST), Profound Medical (PROF), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

How does Spectral AI compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Spectral AI had 5 more articles in the media than Sight Sciences. MarketBeat recorded 6 mentions for Spectral AI and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.89 beat Spectral AI's score of 0.23 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sight Sciences	Very Positive
Spectral AI	Neutral

Spectral AI has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.19	-$38.43M	-$0.71	N/A
Spectral AI	$16.93M	3.81	-$7.57M	-$0.53	N/A

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 13.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sight Sciences currently has a consensus price target of $8.14, indicating a potential upside of 79.38%. Spectral AI has a consensus price target of $4.00, indicating a potential upside of 97.04%. Given Spectral AI's higher probable upside, analysts clearly believe Spectral AI is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sight Sciences has a net margin of -46.83% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Spectral AI	-85.58%	N/A	-72.97%

Sight Sciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Summary

Sight Sciences and Spectral AI tied by winning 8 of the 16 factors compared between the two stocks.

How does Spectral AI compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Spectral AI (NASDAQ:MDAI) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Spectral AI has higher revenue and earnings than Biosig Technologies. Spectral AI is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	6,226.65	-$462.77M	-$9.71	N/A
Spectral AI	$16.93M	3.81	-$7.57M	-$0.53	N/A

Biosig Technologies has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 13.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biosig Technologies has a net margin of 0.00% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Spectral AI	-85.58%	N/A	-72.97%

Biosig Technologies presently has a consensus price target of $8.00, suggesting a potential upside of 483.94%. Spectral AI has a consensus price target of $4.00, suggesting a potential upside of 97.04%. Given Biosig Technologies' higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Spectral AI had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 6 mentions for Spectral AI and 5 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.79 beat Spectral AI's score of 0.23 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Biosig Technologies and Spectral AI tied by winning 7 of the 14 factors compared between the two stocks.

How does Spectral AI compare to RxSight?

RxSight (NASDAQ:RXST) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

RxSight currently has a consensus price target of $9.44, indicating a potential upside of 80.24%. Spectral AI has a consensus price target of $4.00, indicating a potential upside of 97.04%. Given Spectral AI's stronger consensus rating and higher probable upside, analysts plainly believe Spectral AI is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spectral AI has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.61	-$38.94M	-$1.13	N/A
Spectral AI	$16.93M	3.81	-$7.57M	-$0.53	N/A

RxSight has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

RxSight has a net margin of -36.58% compared to Spectral AI's net margin of -85.58%. Spectral AI's return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Spectral AI	-85.58%	N/A	-72.97%

In the previous week, Spectral AI had 4 more articles in the media than RxSight. MarketBeat recorded 6 mentions for Spectral AI and 2 mentions for RxSight. RxSight's average media sentiment score of 0.93 beat Spectral AI's score of 0.23 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of RxSight shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 13.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Spectral AI beats RxSight on 10 of the 16 factors compared between the two stocks.

How does Spectral AI compare to Profound Medical?

Spectral AI (NASDAQ:MDAI) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Spectral AI has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$16.93M	3.81	-$7.57M	-$0.53	N/A
Profound Medical	$16.10M	15.06	-$42.57M	-$1.24	N/A

Spectral AI currently has a consensus price target of $4.00, indicating a potential upside of 97.04%. Profound Medical has a consensus price target of $12.00, indicating a potential upside of 79.91%. Given Spectral AI's higher possible upside, equities analysts clearly believe Spectral AI is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Spectral AI had 4 more articles in the media than Profound Medical. MarketBeat recorded 6 mentions for Spectral AI and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat Spectral AI's score of 0.23 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spectral AI has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Spectral AI has a net margin of -85.58% compared to Profound Medical's net margin of -206.76%. Spectral AI's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Profound Medical	-206.76%	-78.88%	-64.06%

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Spectral AI beats Profound Medical on 11 of the 14 factors compared between the two stocks.

How does Spectral AI compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 13.7% of Spectral AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Orchestra BioMed currently has a consensus target price of $13.60, suggesting a potential upside of 255.09%. Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 97.04%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Orchestra BioMed is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Orchestra BioMed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Spectral AI has a net margin of -85.58% compared to Orchestra BioMed's net margin of -166.96%. Spectral AI's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
Spectral AI	-85.58%	N/A	-72.97%

Spectral AI has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.85	-$52.70M	-$0.97	N/A
Spectral AI	$16.93M	3.81	-$7.57M	-$0.53	N/A

In the previous week, Spectral AI had 5 more articles in the media than Orchestra BioMed. MarketBeat recorded 6 mentions for Spectral AI and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.89 beat Spectral AI's score of 0.23 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Orchestra BioMed	Very Positive
Spectral AI	Neutral

Summary

Spectral AI beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

Get Spectral AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDAI vs. The Competition

Export

Metric	Spectral AI	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.88M	$7.35B	$6.43B	$12.56B
Dividend Yield	N/A	1.28%	2.69%	5.30%
P/E Ratio	-3.83	45.15	21.32	26.62
Price / Sales	3.81	73.79	551.83	113.73
Price / Cash	N/A	25.15	27.44	37.60
Price / Book	-10.68	7.32	9.95	6.88
Net Income	-$7.57M	$157.37M	$3.56B	$336.73M
7 Day Performance	-24.25%	3.48%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	26.74%	2.74%	36.32%	40.26%

Spectral AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDAI Spectral AI	2.3767 of 5 stars	$2.03 -1.9%	$4.00 +97.0%	+29.2%	$65.88M	$16.93M	N/A	83	News Coverage
SGHT Sight Sciences	4.0727 of 5 stars	$4.99 -0.8%	$8.31 +66.6%	+31.0%	$271.51M	$77.36M	N/A	210	Positive News
STEX Biosig Technologies	2.5989 of 5 stars	$1.41 +10.2%	$8.00 +467.4%	N/A	$255.41M	$40K	N/A	50	High Trading Volume
RXST RxSight	3.2895 of 5 stars	$5.99 -1.6%	$9.44 +57.7%	-64.6%	$247.99M	$134.48M	N/A	220
PROF Profound Medical	2.0219 of 5 stars	$6.77 -0.9%	$12.00 +77.3%	+30.2%	$246.02M	$16.10M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDAI) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spectral AI (MDAI) Competitors

MDAI vs. SGHT, STEX, RXST, PROF, and OBIO

How does Spectral AI compare to Sight Sciences?

Summary

How does Spectral AI compare to Biosig Technologies?

Summary

How does Spectral AI compare to RxSight?

Summary

How does Spectral AI compare to Profound Medical?

Summary

How does Spectral AI compare to Orchestra BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spectral AI (MDAI) Competitors

MDAI vs. SGHT, STEX, RXST, PROF, and OBIO

How does Spectral AI compare to Sight Sciences?

Does the media refer more to SGHT or MDAI?

Which has preferable valuation & earnings, SGHT or MDAI?

Do institutionals and insiders believe in SGHT or MDAI?

Do analysts rate SGHT or MDAI?

Is SGHT or MDAI more profitable?

Which has more volatility and risk, SGHT or MDAI?

Summary

How does Spectral AI compare to Biosig Technologies?

Which has preferable earnings & valuation, STEX or MDAI?

Which has more volatility & risk, STEX or MDAI?

Do institutionals and insiders hold more shares of STEX or MDAI?

Is STEX or MDAI more profitable?

Do analysts recommend STEX or MDAI?

Does the media favor STEX or MDAI?

Summary

How does Spectral AI compare to RxSight?

Do analysts recommend RXST or MDAI?

Which has stronger valuation & earnings, RXST or MDAI?

Which has more risk and volatility, RXST or MDAI?

Is RXST or MDAI more profitable?

Does the media favor RXST or MDAI?

Do insiders & institutionals believe in RXST or MDAI?

Summary

How does Spectral AI compare to Profound Medical?

Which has preferable valuation & earnings, MDAI or PROF?

Do analysts rate MDAI or PROF?

Does the media refer more to MDAI or PROF?

Which has more volatility & risk, MDAI or PROF?

Is MDAI or PROF more profitable?

Do insiders and institutionals have more ownership in MDAI or PROF?

Summary

How does Spectral AI compare to Orchestra BioMed?

Do institutionals & insiders have more ownership in OBIO or MDAI?

Do analysts recommend OBIO or MDAI?

Which has more volatility & risk, OBIO or MDAI?

Is OBIO or MDAI more profitable?

Which has higher valuation and earnings, OBIO or MDAI?

Does the media prefer OBIO or MDAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools